Bukwang Pharmaceutical IND
부광약품KRX: 003000· Fiscal year 2025· bukwang.co.kr ↗
Average salary
$47.1K
₩62.7M
▼ 3.4% vs 2024
Employees
650
▲ 11.7% vs 2024
Average tenure
10.3 yrs
Estimated take-home of this pay:$3.2K / monthCalculate →
Workplace
Women's pay (men = 100)65
Women among staff33.5%
Contract staff4.6%
Recent official filings
- 2026-11-17Investor relations (IR) event
- 2026-11-16Quarterly report (2026.09)
- 2026-10-23Preliminary earnings (consolidated)
- 2026-10-15Investor relations (IR) event
- 2026-08-31MajorCourt receivership / bankruptcy
- 2026-08-14MajorCourt receivership / bankruptcy
Quick read
- Average pay is 3% above the median of the companies we track.
- Average pay fell 3.4% from 2024.
- Headcount grew by 68 (11.7%) from 2024.
- Ranks #83 of 238 Healthcare & Pharma companies in this country by pay.
- Revenue grew 25.4% year over year.
- Revenue has grown two years in a row.
- Operating margin was 7.1% in 2025.
- Operating loss of $28.1M in 2023.
Last 3 years
Revenue
Operating income
See the share price on Naver Finance ↗
Investor metrics
2025
- Revenue per employee
- $231.2K
- Net profit per employee
- $14.3K
- Operating margin
- 7.1%
- Net margin
- 6.2%
- ROE
- 3.6%
- Debt-to-equity
- 39.7%
- Equity ratio
- 71.6%
- Payout ratio
- 99.2%
- Dividend per share
- $0
- Dividend yield (as disclosed)
- 3.3%
Per-employee figures use the company headcount, so they run high for groups with many subsidiaries. Not investment advice.